BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29986747)

  • 21. PIK3CA hotspot mutations and cyclooxygenase-2 expression in ovarian clear cell carcinomas: a close association with stromal features.
    Kato N; Sato Y; Kamataki A; Fukase M; Uchigasaki S; Kurose A
    Hum Pathol; 2019 Apr; 86():32-37. PubMed ID: 30496799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
    Itamochi H; Kato M; Nishimura M; Oumi N; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Nonaka M; Kudoh A; Terakawa N; Kigawa J; Harada T
    Hum Cell; 2013 Sep; 26(3):121-7. PubMed ID: 23430509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma.
    Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2012 Aug; 32(8):3091-5. PubMed ID: 22843878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
    Murakami K; Kanto A; Sakai K; Miyagawa C; Takaya H; Nakai H; Kotani Y; Nishio K; Matsumura N
    Mod Pathol; 2021 Nov; 34(11):2071-2079. PubMed ID: 34172890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
    Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
    Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
    Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
    Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
    Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
    Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma.
    Kuo KT; Mao TL; Chen X; Feng Y; Nakayama K; Wang Y; Glas R; Ma MJ; Kurman RJ; Shih IeM; Wang TL
    Clin Cancer Res; 2010 Apr; 16(7):1997-2008. PubMed ID: 20233889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
    Kuroda T; Kohno T
    Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.
    Jones S; Wang TL; Shih IeM; Mao TL; Nakayama K; Roden R; Glas R; Slamon D; Diaz LA; Vogelstein B; Kinzler KW; Velculescu VE; Papadopoulos N
    Science; 2010 Oct; 330(6001):228-31. PubMed ID: 20826764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.
    Jiang G; Huang Z; Zhang S; Wang L
    Cancer Invest; 2013 Dec; 31(10):639-44. PubMed ID: 24299208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
    Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
    Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR‑381 regulates cell motility, growth and colony formation through PIK3CA in endometriosis‑associated clear cell and endometrioid ovarian cancer.
    Hsu CY; Hsieh TH; Er TK; Chen HS; Tsai CC; Tsai EM
    Oncol Rep; 2018 Dec; 40(6):3734-3742. PubMed ID: 30542723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebellar Metastasis From Ovarian Carcinoma Harboring PIK3CA-Activating Mutation: A "Clear" Explanation for Unexpected "Vertigo".
    Piermattei A; Santoro A; Angelico G; Inzani F; Valente M; Pettinato A; Vatrano S; Scambia G; Fraggetta F; Zannoni GF
    Int J Gynecol Pathol; 2020 Jan; 39(1):68-71. PubMed ID: 30252727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinguishing the progression of an endometrioma: Benign or malignant?
    Bastu E; Onder S; Demiral I; Ozsurmeli M; Keskin G; Takmaz O; Ozaltin S; Gorgen H; Gungor M; Yavuz E; Buyru F
    Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():79-84. PubMed ID: 30245441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer.
    Schnack TH; Oliveira DNP; Christiansen AP; Høgdall C; Høgdall E
    Cancer Genet; 2023 Nov; 278-279():9-16. PubMed ID: 37567101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.